American Diabetes Association
Browse

Type 1 diabetes genetic risk contributes to phenotypic presentation in monogenic autoimmune diabetes

Download (583.73 kB)
figure
posted on 2024-11-12, 18:48 authored by Amber M Luckett, Gareth Hawkes, Harry D Green, Elisa De Franco, William A Hagopian, Bart O Roep, Michael N Weedon, Richard A Oram, Matthew B Johnson, the EXE-T1D consortium

Disease-causing variants in key immune homeostasis genes can lead to monogenic autoimmune diabetes. Some individuals carrying disease-causing variants do not develop autoimmune diabetes, even though they develop other autoimmune disease. We aimed to determine whether type 1 diabetes polygenic risk contributes to phenotypic presentation in monogenic autoimmune diabetes. We used a 67 SNP type 1 diabetes genetic risk score (T1D-GRS) to determine polygenic risk in 62 individuals with monogenic autoimmune diabetes and 180 non-autoimmune neonatal diabetes (NDM) controls. We used population-based controls (n=10,405) and individuals with type 1 diabetes (n=285) as a comparator. Individuals with monogenic autoimmune diabetes had higher T1D-GRSs compared to non-autoimmune NDM (mean 11.3 vs. 9.8; P=1.7x10-5) and controls (mean 10.3; P=7.5x10-6) but were markedly lower than type 1 diabetes (14.9; P= 3.3 x 10-21). These differences were explained by monogenic autoimmune diabetes cases having higher Class II HLA genetic risk, specifically from the DRB1*03:01-DQA1*05:01-DQB1*02:01 haplotype (DR3-DQ2) (P<0.01). In the presence of monogenic autoimmunity, the polygenic class II HLA susceptibility contributes to development of autoimmune diabetes. This suggests a role of class II HLA in targeting the dysregulated immune response towards the beta-cell.

Funding

MBJ is a Diabetes UK and JDRF international RD Lawrence Fellow. EDF is a Diabetes UK RD Lawrence Fellow (19/005971) and the recipient of an EFSD/Novo Nordisk Foundation Future Leaders Award (NNF23SA0087432). RAO is a Diabetes UK Harry Keen Fellow (16/0005529). RAO and MNW had a UK Medical Research Council (MRC) Confidence in Concept grant to develop a type 1 diabetes GRS biochip with Randox and have ongoing research funding from Randox R&D. WAH is supported by US NIH grant 5U01DK128847 and by an unrestricted research grant from Sanofi USA. AML is funded by a PhD studentship from Randox Laboratories Ltd.

History